This stock had a hot initial public offering late last year, and though it has surrendered all the gains, it still offers an outstanding energy point. Payoneer Global Inc. (NASDAQ: PAYO) operates a cross-border payment and commerce-enabling platform that facilitates digital businesses, online sellers, and freelancers worldwide to receive and manage their international payments.
The company delivers a suite of services that includes cross-border payments, working capital, tax solutions, merchant services and risk management. Its platform offers freelancers, web development companies and service providers with options to pay and get paid by companies and marketplaces worldwide. It also offers a solution for online advertisers, affiliates, publishers and content creators for getting paid by digital marketing platforms.
Payoneer Global also provides its platform for online sellers to receive payments from e-commerce marketplaces to one consolidated account; to monitor performance of multiple stores at a common place; to pay suppliers and contractors; to access funds directly to a local bank account; to view upcoming payments and payment history for e-commerce sites; and to receive payments for items purchased in stores. In addition, it offers working capital services.
Cantor Fitzgerald started coverage this week and has a $13 price target. The consensus target is just higher at $14, and on Friday the stock closed at $9.44.
Electric Vehicle Buying Surge May Be Huge for Power Companies: 5 Top Dividend Stocks to Buy
Shares of this small-cap clinical-stage biopharmaceutical company could have monster upside potential. Viking Therapeutics Inc. (NASDAQ: VKTX) is focused on the development of novel therapies for metabolic and endocrine disorders.
Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRA), which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as non-alcoholic fatty liver disease.
The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase 2 clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. Its VK0612 is an orally available Phase 2b-ready drug candidate for type 2 diabetes, and VK0214 is an orally available tissue and receptor-subtype selective agonist of the TRA for X-linked adrenoleukodystrophy.
BTIG Research just started coverage on Viking Therapeutics stock, and its huge $20 price target is above the $18.92 consensus figure. On Friday, shares closed the trading session at $6.15.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.